These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

649 related articles for article (PubMed ID: 30352896)

  • 1. Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials.
    Beck RW; Bergenstal RM; Riddlesworth TD; Kollman C; Li Z; Brown AS; Close KL
    Diabetes Care; 2019 Mar; 42(3):400-405. PubMed ID: 30352896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences for Percentage Times in Glycemic Range Between Continuous Glucose Monitoring and Capillary Blood Glucose Monitoring in Adults with Type 1 Diabetes: Analysis of the REPLACE-BG Dataset.
    Avari P; Uduku C; George D; Herrero P; Reddy M; Oliver N
    Diabetes Technol Ther; 2020 Mar; 22(3):222-227. PubMed ID: 31613142
    [No Abstract]   [Full Text] [Related]  

  • 3. The Relationships Between Time in Range, Hyperglycemia Metrics, and HbA1c.
    Beck RW; Bergenstal RM; Cheng P; Kollman C; Carlson AL; Johnson ML; Rodbard D
    J Diabetes Sci Technol; 2019 Jul; 13(4):614-626. PubMed ID: 30636519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial.
    Lachin JM; Bebu I; Bergenstal RM; Pop-Busui R; Service FJ; Zinman B; Nathan DM;
    Diabetes Care; 2017 Jun; 40(6):777-783. PubMed ID: 28404658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycated Hemoglobin A1c Time in Range and Dementia in Older Adults With Diabetes.
    Underwood PC; Zhang L; Mohr DC; Prentice JC; Nelson RE; Budson AE; Conlin PR
    JAMA Netw Open; 2024 Aug; 7(8):e2425354. PubMed ID: 39093563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Relationship of Hemoglobin A1C to Time-in-Range in Patients with Diabetes.
    Vigersky RA; McMahon C
    Diabetes Technol Ther; 2019 Feb; 21(2):81-85. PubMed ID: 30575414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Estimated Time-in-Range Capillary Glucose Levels Versus HbA1c With Progression of Microvascular Complications in the Diabetes Control and Complications Trial.
    Lachin JM; Bebu I; Gao X; Nathan DM; Zinman B;
    Diabetes Care; 2022 Oct; 45(10):2445-2448. PubMed ID: 35972222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metrics Beyond Hemoglobin A1C in Diabetes Management: Time in Range, Hypoglycemia, and Other Parameters.
    Wright LA; Hirsch IB
    Diabetes Technol Ther; 2017 May; 19(S2):S16-S26. PubMed ID: 28541136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial.
    Diabetes; 1996 Oct; 45(10):1289-98. PubMed ID: 8826962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translating glycated hemoglobin A1c into time spent in glucose target range: A multicenter study.
    Petersson J; Åkesson K; Sundberg F; Särnblad S
    Pediatr Diabetes; 2019 May; 20(3):339-344. PubMed ID: 30652407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PDM-ProValue meets cardiovascular outcome trials in diabetes.
    Fritzen K; Schnell O
    Cardiovasc Diabetol; 2019 Jan; 18(1):10. PubMed ID: 30691463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive Value of Fasting Glucose, Postload Glucose, and Hemoglobin A
    Lu J; He J; Li M; Tang X; Hu R; Shi L; Su Q; Peng K; Xu M; Xu Y; Chen Y; Yu X; Yan L; Wang T; Zhao Z; Qin G; Wan Q; Chen G; Dai M; Zhang D; Gao Z; Wang G; Shen F; Luo Z; Qin Y; Chen L; Huo Y; Li Q; Ye Z; Zhang Y; Du R; Cheng D; Liu C; Wang Y; Wu S; Yang T; Deng H; Li D; Lai S; Bloomgarden ZT; Chen L; Zhao J; Mu Y; Ning G; Wang W; Bi Y;
    Diabetes Care; 2019 Aug; 42(8):1539-1548. PubMed ID: 31152120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time in range, as measured by continuous glucose monitor, as a predictor of microvascular complications in type 2 diabetes: a systematic review.
    Raj R; Mishra R; Jha N; Joshi V; Correa R; Kern PA
    BMJ Open Diabetes Res Care; 2022 Jan; 10(1):. PubMed ID: 34980591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positioning time in range in diabetes management.
    Advani A
    Diabetologia; 2020 Feb; 63(2):242-252. PubMed ID: 31701199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic thresholds for diabetes: the association of retinopathy and albuminuria with glycaemia.
    Tapp RJ; Zimmet PZ; Harper CA; de Courten MP; McCarty DJ; Balkau B; Taylor HR; Welborn TA; Shaw JE;
    Diabetes Res Clin Pract; 2006 Sep; 73(3):315-21. PubMed ID: 16644057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Making sense of glucose metrics in diabetes: linkage between postprandial glucose (PPG), time in range (TIR) & hemoglobin A1c (A1C).
    Martens TW; Bergenstal RM; Pearson T; Carlson AL; Scheiner G; Carlos C; Liao B; Syring K; Pollom RD
    Postgrad Med; 2021 Apr; 133(3):253-264. PubMed ID: 33315495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of the risk to develop diabetes-related late complications by means of the glucose pentagon model: analysis of data from the Juvenile Diabetes Research Foundation continuous glucose monitoring study.
    Thomas A; Heinemann L
    J Diabetes Sci Technol; 2012 May; 6(3):572-80. PubMed ID: 22768888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program.
    Danne T; Cariou B; Buse JB; Garg SK; Rosenstock J; Banks P; Kushner JA; McGuire DK; Peters AL; Sawhney S; Strumph P
    Diabetes Care; 2019 May; 42(5):919-930. PubMed ID: 30833371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased Hemoglobin A
    Prentice JC; Mohr DC; Zhang L; Li D; Legler A; Nelson RE; Conlin PR
    Diabetes Care; 2021 Aug; 44(8):1750-1756. PubMed ID: 34127496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What are the clinical, quality-of-life, and cost consequences of 30 years of excellent vs. poor glycemic control in type 1 diabetes?
    Herman WH; Braffett BH; Kuo S; Lee JM; Brandle M; Jacobson AM; Prosser LA; Lachin JM
    J Diabetes Complications; 2018 Oct; 32(10):911-915. PubMed ID: 30082172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.